Coala Life: Validated Cost-Effectiveness - Redeye

Redeye is encouraged to learn that a health economic analysis carried out by the Swedish Dental and Pharmaceutical Benefits Agency shows cost-effectiveness of using Coala Heart Monitor Pro in primary care. With yet another validation in place, we continue to argue that Coala Life has excellent growth prospects in 2022 and onwards and see the share as very attractive at current share price levels.

Länk till analysen i sin helhet: https://www.redeye.se/research/832388/coala-life-validated-cost-effectiveness?utm_source=finwire&utm_medium=RSS